Malignant pleural mesothelioma: Current treatments and emerging drugs

Expert Opinion on Emerging Drugs

Volumn 14, Issue 3, 2009, Pages 423-437

  Belli, Carmen ^a   Fennell, Dean ^b   Giovannini, Monica ^a   Gaudino, Giovanni ^c   Mutti, Luciano ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d Local Health Unit   (Italy)

Author keywords

Chemotherapy; EGFR; Malignant mesothelioma; Mesothelin; mTOR; PDGFR; Proteosoma; Target therapy; VEGFR

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; RALTITREXED; RANPIRNASE; SEMAXANIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VATALANIB; VINBLASTINE; VINCA ALKALOID; VORINOSTAT;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; EDEMA; EPISTAXIS; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG CANCER; MALIGNANT MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 69949117635     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903074563     Document Type: Review

References (100)

1. Ramos-Nino M, Timblin C, Mossman B. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002;62:6065-6069 (Pubitemid 35244454)
2. Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006;103:10397-10402 •• This paper is considered of interest because it describes the mechanism of asbestos carcinogenesis and the inhibition of NF-kB molecular pathway, which allowed the discovery of drugs targeting this pathway. (Pubitemid 44051178)
3. Xu A, Zhou H, Yu DZ, et al. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect 2002;110:1003-1008 • This is an interesting paper describing the mechanism of asbestos carcinogenesis induced by production of reactive mutagenic oxygen. (Pubitemid 35175042)
4. Kroczynska B, Cutrone R, Boccetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelioma cells and causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103:14128-14133 (Pubitemid 44452991)
5. Barbanti-Brodano G, Sabbioni S, Martini F, et al. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 2004;318:1-9 (Pubitemid 38234254)
6. Bocchetta M, Miele L, Pass HI, et al. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003;22:81-89 (Pubitemid 36152886)
7. Bocchetta M, Eliasz S, De Marco MA, et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008;68:1022-1029 (Pubitemid 351272219)
8. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672 • This paper is considered of interest because it describes the increased incidence of MPM.
9. Flores RM. The role of PET in the surgical management of malignant mesothelioma. Lung Cancer 2005;49(Suppl 1):S27-32
10. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998;113(Suppl 1):61S-5S
11. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 2004;14:567-573
12. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A lung cancer study group trial. J Thorac Cardiovasc Surg 1991;102:1-9
13. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-92; discussion 1692-1693
14. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-146 (Pubitemid 38881208)
15. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795 (Pubitemid 33590380)
16. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 2007;68:1366-1374
17. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-645 (Pubitemid 43795851)
18. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995;108:754-758
19. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84:18-22 (Pubitemid 47030694)
20. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004;91:9-10 (Pubitemid 39013037)
21. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644 •• These two papers are of considerable interest because they permitted the clinical use of antifolate drugs in the treatment of MPM. (Pubitemid 46606305)
22. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III Study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889 •• These two papers are of considerable interest because they permitted the clinical use of antifolate drugs in the treatment of MPM. (Pubitemid 46260274)
23. Tomek S, Emri S, Krejcy K, et al. Chemotherapy for malignant pleural mesothelioma: past results and recent development. Br J Cancer 2003;88:167-174 (Pubitemid 36258399)
24. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-3917
25. Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003;5:98-106
26. Yap BS, Benjamin RS, Byrne M, et al. The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer 1978;42:1692-1696 • This is an interesting paper describing the role of antracycline in the treatment of MPM.
27. Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;3:136-147 (Pubitemid 351330666)
28. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44-45 (Pubitemid 351920221)
29. Castagneto B, Zai S, Degiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005;28:223-226 (Pubitemid 40800471)
30. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60:259-263 (Pubitemid 351609140)
31. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-496 (Pubitemid 35052715)
32. van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-345 (Pubitemid 34187648)
33. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003;97:2791-2797 (Pubitemid 36605147)
34. Jänne PA, Simon GR, Langer CJ, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesotelioma. J Clin Oncol 2008;26:1465-1471
35. Andreopoulou E, Ross PJ, O'Brien ME, et al. The palliative benefit of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004;15:1406-1412 (Pubitemid 39295029)
36. Scagliotti GV, Shin D-M, Kindler HL, et al. Phase II study of Pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561
37. Baas P, Ardizzoni A, Grossi F, et al. EORTC Lung Cancer Group: the activit of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003;39:353-357
38. Calvert AH, Hughes AN, Calvert PM, et al. ALIMTA in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer 2000;29(Suppl 2):73-74
39. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349-354 (Pubitemid 46606165)
40. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24(9):1443-1448 •• These two articles are particulary interesting because they showed that the combination cisplatin and pemetrexed has similar clinical efficacy as carboplatin and pemetrexed.
41. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-373 •• These two articles are particulary interesting because they showed that the combination cisplatin and pemetrexed has similar clinical efficacy as carboplatin and pemetrexed. (Pubitemid 351201722)
42. Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008;99:51-56 (Pubitemid 351920240)
43. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-927 (Pubitemid 40903918)
44. Giaccone G, O'Brien ME, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002;38(Suppl 8):S19-24 (Pubitemid 41127956)
45. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984;15:961-964
46. Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005;48:429-434 (Pubitemid 40693630)
47. Sørensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985;69(12):1431-1432 (Pubitemid 16163084)
48. Sørensen JB, Sundstrom S, Perell K, et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2:147-152 (Pubitemid 47181344)
49. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007;109:93-99 (Pubitemid 46120198)
50. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704
51. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002;20:274-281
52. Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival [abstract 2274]. Proc Am Soc Clin Oncol 2000;19:577a
53. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998;273:14484-14494 (Pubitemid 28319170)
54. Dazzi H, Hasleton PS, Tachter N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924-926 (Pubitemid 20197007)
55. Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006;54:399-407
56. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101) [abstract 2535]. Proc Am Soc Clin Oncol 2003;22:630 •• This article demonstrated that gefitinib is not effective in the treatment of MPM.
57. Butnor KJ, Burchette JL, Sporn TA, et al. The spectrum of kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004;128:538-543 •• These two articles evaluate the role of new molecular pathways activated in MPM, which might be involved in pathogenesis of this tumor.
58. Langerak AW, van der Linden-van Beurden CA, Vesnel MA. Regulation of differential expression of platelet-derived growth factor alpha and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996;1305:63-70 •• These two articles evaluate the role of new molecular pathways activated in MPM, which might be involved in pathogenesis of this tumor.
59. Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? Surg Oncol 1993;2:235-240
60. Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB act as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β-integrin 3β1 interaction. Clin Exp Metastasis 1998;16:529-539 (Pubitemid 29009588)
61. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262 (Pubitemid 33044331)
62. Catalano A, Rodinolis S, Rippo AR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrugresistant malignant mesothelioma cells. J Biol Chem 2004;279:46706-46714 (Pubitemid 39518318)
63. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:6080-6089
64. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934 •• These three papers are considered of considerable interest because they discuss the synergistic effect of chemotherapy and new drugs resposible for inhibiton of PDGFR and c-KIT pathways in MPM. (Pubitemid 32691937)
65. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-5484 •• These three papers are considered of considerable interest because they discuss the synergistic effect of chemotherapy and new drugs resposible for inhibiton of PDGFR and c-KIT pathways in MPM.
66. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-3787 •• These three papers are considered of considerable interest because they discuss the synergistic effect of chemotherapy and new drugs resposible for inhibiton of PDGFR and c-KIT pathways in MPM. (Pubitemid 37169248)
67. Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999;189:72-78 (Pubitemid 29406822)
68. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475 •• These three articles are interesting because they discuss the role of angiogenesis in MPM and its role as a prognostic factor. (Pubitemid 32266815)
69. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-868 •• These three articles are interesting because they discuss the role of angiogenesis in MPM and its role as a prognostic factor. (Pubitemid 33010554)
70. Branchaud RM, MacDonald JL, Kane AB. Induction of angiogenesis by intraperitoneal injection of asbestos fibers. FASEB J 1989;3:1747-1752 •• This is the first paper that describes a link between asbestos fibers and agiogenesis.
71. Roff M, Thompson J, Rodriguez MS, et al. Role of IkappaB alpha ubiquitination in signal-induced activation of NF-kappaB in vivo. J Biol Chem 1996;271:7844-7850 (Pubitemid 26107067)
72. An B, Goldfarb RH, Simian R, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induces apoptosis in transformed, but not normal, human fibroblast. Cell Death Differ 1998;5:1062-1075
73. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274
74. Strahl BD, Allis CD. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;403:41-45
75. Rippo MR, Moretti S, Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2003;23:7753-7760 (Pubitemid 39457025)
76. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-3942
77. Jane PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-5247 (Pubitemid 35024597)
78. Garland L, Rankin C, Scott K, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-2413 •• This article demonstrated that erlotinib is not effective for treatment of MPM. (Pubitemid 46999211)
79. Cortese JF, Gowda AL, Wali A, et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006;(118):521-522 •• This interesting article gives a possible explanation for absence of any benefit of using EGFR-TKIs. (Pubitemid 41779097)
80. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma [abstract 912]. Proc Am Soc Clin Oncol 2003;22
81. Villano J, Husain AN, Stadler WM, et al. A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) [abstract 7200]. Proc Am Soc Clin Oncol 2004;663
82. Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-86 (Pubitemid 41297473)
83. Porta C, Mutti L, Tassi G. Negative results of an italian group for mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-150 (Pubitemid 44796113)
84. Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62:690-695 •• This paper is considered of considerable interest because they discuss the synergistic effect of chemotherapy and new drugs resposible for inhibiton of PDGFR and c-KIT pathways in MPM. (Pubitemid 47235011)
85. Catalano A, Gianni W, Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenetic treatments. Crit Rev Oncol Hematol 2004;50:101-109 (Pubitemid 38638737)
86. Kindler HL, Karrison T, Lu C, et al. A multicenter, double-bind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM) [abstract 7019]. Proc Am Soc Clin Oncol 2005;23
87. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-814
88. Kindler HL, Chien K, Stadler WM, et al. SU5416 in malignant mesothelioma: a Univeristy of Chicago phase II consortium study [abstract 1359]. Proc Am Soc Clin Oncol 2001;20
89. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667 (Pubitemid 34260548)
90. Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) [abstract 8063]. J Clin Oncol 2008;26(Suppl):439s
91. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol 2006;24(18S):7081
92. Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-873
93. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005;48:291-296 (Pubitemid 40501820)
94. Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies [abstract]. Lung Cancer 2003;41(Suppl 2):S11
95. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor Bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008;61:549-558
96. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-2347 (Pubitemid 41115390)
97. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931 (Pubitemid 46218695)
98. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-5149 (Pubitemid 47502082)
99. Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-4701 (Pubitemid 44297823)
100. Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995;36:488